Dimitrakov Jordan, Joffe Hylton V, Soldin Steven J, Bolus Roger, Buffington C A Tony, Nickel J Curtis
Harvard Urological Diseases Research Center, Children's Hospital Boston, Boston, Massachusetts 02115, USA.
Urology. 2008 Feb;71(2):261-6. doi: 10.1016/j.urology.2007.09.025.
To identify adrenocortical hormone abnormalities as indicators of endocrine dysfunction in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
We simultaneously measured the serum concentrations of 12 steroids in patients with CP/CPPS and controls, using isotope dilution liquid chromatography, followed by atmospheric pressure photospray ionization and tandem mass spectrometry.
We evaluated 27 patients with CP/CPPS and 29 age-matched asymptomatic healthy controls. In the mineralocorticoid pathway, progesterone was significantly greater, and the corticosterone and aldosterone concentrations were significantly lower, in the patients with CP/CPPS than in the controls. In the glucocorticoid pathway, 11-deoxycortisol was significantly lower and the cortisol concentrations were not different between the patients and controls. In the sex steroid pathway, the androstenedione and testosterone concentrations were significantly greater in those with CP/CPPS than in the controls. The estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate concentrations were not different between the patients and controls. The National Institutes of Health-Chronic Prostatitis Symptom Index total and pain domain scores correlated positively with the 17-hydroxyprogesterone and aldosterone (P <0.001) and negatively with the cortisol (P <0.001) concentrations.
Our results suggest reduced activity of CYP21A2 (P450c21), the enzyme that converts progesterone to corticosterone and 17-hydroxyprogesterone to 11-deoxycortisol. Furthermore, these results provide insights into the biologic basis of CP/CPPS. Follow-up studies should explore the possibility that patients with CP/CPPS meet the diagnostic criteria for nonclassic congenital adrenal hyperplasia and whether the hormonal findings improve or worsen in parallel with symptom severity.
确定肾上腺皮质激素异常作为慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)内分泌功能障碍的指标。
我们使用同位素稀释液相色谱法,随后进行大气压光喷雾电离和串联质谱法,同时测量CP/CPPS患者和对照组血清中12种类固醇的浓度。
我们评估了27例CP/CPPS患者和29例年龄匹配的无症状健康对照。在盐皮质激素途径中,CP/CPPS患者的孕酮显著升高,而皮质酮和醛固酮浓度显著低于对照组。在糖皮质激素途径中,11-脱氧皮质醇显著降低,患者和对照组的皮质醇浓度无差异。在性类固醇途径中,CP/CPPS患者的雄烯二酮和睾酮浓度显著高于对照组。患者和对照组之间的雌二醇、脱氢表雄酮和硫酸脱氢表雄酮浓度无差异。美国国立卫生研究院慢性前列腺炎症状指数总分和疼痛领域评分与17-羟孕酮和醛固酮呈正相关(P<0.001),与皮质醇呈负相关(P<0.001)。
我们的结果表明,将孕酮转化为皮质酮以及将17-羟孕酮转化为11-脱氧皮质醇的CYP21A2(P450c21)酶活性降低。此外,这些结果为CP/CPPS的生物学基础提供了见解。后续研究应探讨CP/CPPS患者是否符合非经典先天性肾上腺皮质增生的诊断标准,以及激素结果是否与症状严重程度平行改善或恶化。